Correction to: Fully-automated synthesis of 177Lu labelled FAPI derivatives on the module modular lab-Eazy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2365-421X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Fully-automated synthesis of 177Lu labelled FAPI derivatives on the module modular lab-Eazy ; volume:6 ; number:1 ; day:19 ; month:5 ; year:2021 ; pages:1-2 ; date:12.2021
EJNMMI radiopharmacy and chemistry ; 6, Heft 1 (19.5.2021), 1-2, 12.2021
- Urheber
-
Eryilmaz, Kurtulus
Kilbas, Benan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s41181-021-00134-z
- URN
-
urn:nbn:de:101:1-2021091807385269843106
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Eryilmaz, Kurtulus
- Kilbas, Benan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Fully-automated synthesis of 177Lu labelled FAPI derivatives on the module modular lab-Eazy
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model
Fully-automated production of [68Ga]Ga-FAPI-46 for clinical application
Fully automated radiosynthesis of [68Ga]Ga-FAPI-46 with cyclotron produced gallium
Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
Investigation of models with temporal and spatial interference in image based dosimetry of 177Lu-labelled radioligand therapies
Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile
FAPI-PET in cardiovascular disease
Labelled love
Fully-automated synthesis of 177Lu labelled FAPI derivatives on the module modular lab-Eazy
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model
Fully-automated production of [68Ga]Ga-FAPI-46 for clinical application
Fully automated radiosynthesis of [68Ga]Ga-FAPI-46 with cyclotron produced gallium
Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
Investigation of models with temporal and spatial interference in image based dosimetry of 177Lu-labelled radioligand therapies
Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile
FAPI-PET in cardiovascular disease
Labelled love
Fully-automated synthesis of 177Lu labelled FAPI derivatives on the module modular lab-Eazy
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model
Fully-automated production of [68Ga]Ga-FAPI-46 for clinical application
Fully automated radiosynthesis of [68Ga]Ga-FAPI-46 with cyclotron produced gallium
Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
Investigation of models with temporal and spatial interference in image based dosimetry of 177Lu-labelled radioligand therapies
Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile
FAPI-PET in cardiovascular disease